The U.S. Food and Drug Administration (FDA) recently approved Allergan’s ubrogepant (Ubrelvy) for treatment of acute migraine with or without visual disruptions (aura).

The FDA’s acting director of the Office of Neuroscience describes the impact of the approval: “Migraine is an often disabling condition that affects an estimated 37 million people in the U.S…Ubrelvy represents an important new option for the acute treatment of migraine in adults, as it is the first drug in its class approved for this indication. The FDA is pleased to approve a novel treatment for patients suffering from migraine and will continue to work with stakeholders to promote the development of new safe and effective migraine therapies.”

Please read more about ubrogepant’s here.

Source:
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-migraine